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Introduction
Menopause is defined as a  12-month period of 
time when menstruation permanently ceases, and it 
physiologically occurs between 45 and 55 years of age. 
However, in some cases menopause may be caused by 
external factors – for example, gonadotoxic treatment 
that damages ovarian tissue leading to irreversible loss 
of its hormonal and reproductive function. Patients ex-
posed to treatment that may impair reproductive func-
tion are most frequently oncological patients [1].
Different types of cancer dominate in different age 
groups. Among young adults, i.e. 25-44 years old, wom-
en are most frequently diagnosed with breast cancer 
(45%), melanoma (9%), and cervical cancer (8%) [2].
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Abstract
Introduction: Menopause is defined as a 12-month period of time when menstruation permanently ceases. In 
some cases, menopause may be caused by external factors – for example gonadotoxic treatment that irreversibly 
damages ovarian tissue leading to loss of its hormonal and reproductive function. Oncofertility is a discipline that 
merges oncology and reproductive medicine, giving patients a chance to experience parenthood after gonadotoxic 
treatment is finished. 
Aim of the study: The purpose of the study is to present the implementation and first outcomes of the  
Oncofertility Programme in the University Clinic of Endocrinological Gynaecology and Gynaecology, University  
Hospital in Krakow, Poland.
Material and methods: Patients interested in fertility preservation have been consulted in the University Clinic 
of Endocrinological Gynaecology and Gynaecology in Krakow since April 2016. Preliminary qualification to one of 
the available methods (embryo cryopreservation, oocyte cryopreservation, ovarian tissue cryopreservation) was 
conducted. Patients declaring a wish to join the programme were then referred to one of the three infertility treat-
ment centres cooperating with the University Clinic, in order to undergo the chosen procedure.
Results: During a period of 24 months, 18 patients were consulted. The youngest consulted patient was 20 years 
old, the oldest 39. Two years after the first consultation, a telephone survey among consulted patients was carried out 
to verify whether the patients finally underwent oncofertility procedures, and to ask about their reproductive status.
Conclusions: The problem of fertility issues being inadequately addressed results in low referral rates to on-
cofertility programmes. Attempts to raise awareness of oncofertility possibilities among oncologists should be 
undertaken because critically few patients are being referred to oncofertility centres.
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Advances in cancer treatment allow patients to be 
cured and live longer. Survival rates are known to be 
highest for patients aged between 15 and 44 years of 
age, with five-year survival ranging from 60% to 82% 
according to age, tumour site, and country of treat-
ment. Nevertheless, cancer therapies often come with 
undesirable side effects. Among these, infertility may 
affect up to 80% of cancer survivors [3].
Oncofertility, a new discipline that merges oncology 
and reproductive medicine, gives adolescent and young 
adult patients a chance to experience the joy of parent-
hood after the treatment is finished.
Oncofertility was first named in 2015 by the Ameri-
can Society of Reproductive Medicine. The initiator and 
promoter of the discipline is Prof. Theresa Woodruff, the 
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Dean and Associate Provost for Graduate Education in 
the Graduate School at Northwestern University.
The aim of this study is to present the process of 
implementation and first outcomes of the Oncofertility 
Programme in the University Clinic of Endocrinological 
Gynaecology and Gynaecology, University Hospital in 
Krakow, Poland.
Material and methods
Patients interested in fertility preservation, before 
the treatment that may impair reproductive potential, 
have been consulted in the University Clinic of Endo-
crinological Gynaecology and Gynaecology, University 
Hospital in Krakow since April 2016. Information about 
diagnosis, planned treatment, procreative plans, and 
lab results were obtained. Patients were informed about 
available fertility preservation procedures. Based on the 
clinical picture and patient’s preference, preliminary 
qualification to one of the available methods (embryo 
cryopreservation, oocyte cryopreservation, ovarian tis-
sue cryopreservation) was conducted. Patients declar-
ing a wish to join the programme were then referred to 
one of the three infertility treatment centres cooperat-
ing with the clinic, in order to undergo the chosen on-
cofertility procedure. This is due to the fact that these 
kinds of procedures can only be conducted commer-
cially because they are not covered by national health 
insurance according to Polish regulations. The study ob-
tained Institutional Review Board consent in June 2015 
(no. 122.6120.94.2015 and 122.6120.95.2015).
Results
During a period of 24 months, 18 patients were con-
sulted. Diagnoses included oncological diseases: six cas-
es of ovarian cancer (33%), three cases of breast cancer 
(17%), three cases of Hodgkin lymphoma (17%), and 
one of cervical cancer (5%); rheumatological diseases: 
one case of systemic lupus erythromatosus (SLE) (5%), 
one mixed connective tissue disease (MCTD) (5%), one 
Takayasu disease (5%), as well as one case of multiple 
sclerosis (5%) – the patient before myeloablation due to 
planned haematopoietic stem cell transplantation and 
one patient (5%) with BRCA1 gene mutation (Fig. 1).
The youngest consulted patient was 20 years old, 
the oldest was 39. Mean age was 31 years, and the me-
dian value was 34 years.
Patients were referred to the Clinic by different spe-
cialists: six (33%) by oncologist, four (22%) by gynaecolo-
gist, three (17%) by gynaecological oncologist, two (11%) 
by internist, one (5%) by rheumatologist, one (5%) by 
haematologist, and one (5%) by neurologist (Fig. 2).
Two of the consulted patients (11%) had procrea-
tive plans at the time of consultation. One patient (5%) 
already had children.
Time from diagnosis to oncofertility consultation 
differed between patients from two days to four years 
in one case. Mean time was 154 days, median value 
25 days.
Preliminary qualifications
Until March 2018, 11 patients (61% of the consult-
ed patients) were qualified to the programme. Initially 
five patients (45% of the included to the programme) 
chose oocyte cryopreservation as a  fertility preserva-
tion method because they did not have a partner. Three 
(27%) patients opted for ovarian tissue cryopreserva-
tion due to contraindications for hormonal stimulation 
or lack of partner, two (18%) couples initially chose 
embryo cryopreservation as the most effective fertility 
preservation method [4].
Four patients (22% of the consulted) did not ex-
press the wish to be included to the programme, in one 
case (5%) fertility preservation was contraindicated 
due to medical reasons, and two patients were lost to 
follow-up.
Two years after the first consultation, a telephone 
survey among all consulted patients was carried out in 
Fig. 1. Diagnoses of the consulted patients Fig. 2. Specialists referring patients for consultations
Number of patients Number of patients
7
6
5
4
3
2
1
0
7
6
5
4
3
2
1
0
ov
ari
an
 ca
nc
er
on
co
log
ist
bre
as
t c
an
ce
r
gy
na
ec
olo
gis
tSL
E
rhe
um
ato
log
ist
mu
ltip
le 
scl
ero
sis
ne
uro
log
ist
Ho
dg
kin
 ly
mp
ho
ma
gy
na
ec
olo
gic
al…MC
TD
BR
CA
1 m
ut
ati
on
ce
rvi
ca
l c
an
ce
r
int
ern
ist
Ta
ka
ya
su
 di
se
as
e
ha
em
ato
log
ist
Menopause Review/Przegląd Menopauzalny 18(2) 2019
65
order to verify whether the patients initially included 
in the programme finally decided to undergo fertility 
preserving procedures, ask about patients’ current re-
productive plans, and monitor their general health con-
dition.
From 18 patients, two remained unavailable despite 
several attempts to contact them.
Follow-up
Four patients ultimately underwent oncofertility 
procedures (Fig. 3). Three of them were qualified for 
oocyte cryopreservation (because they did not have 
a partner at the time) and one for ovarian tissue cryo-
preservation because the immediate onset of the treat-
ment was required.
One patient with cervical cancer underwent fertili-
ty-sparing surgery (radical laparoscopic trachelectomy 
with pelvic lymphadenectomy). No subsequent treat-
ment was required. The patient has remained asymp-
tomatic for 1.5 years and is currently planning to get 
pregnant.
None of the patients is planning to utilise preserved 
material in the forthcoming six months. 
One patient did not undergo initially planned em-
bryo cryopreservation at that time because state dona-
tion for in vitro fertilisation procedures ceased and the 
patient could not afford to cover the expenses associ-
ated with IVF.
Two of the patients consulted in the Clinic had al-
ready delivered healthy babies. None of these patients 
had undergone oncofertility procedures. Both con-
ceived spontaneously during remission of the disease. 
Both pregnancies had undisturbed course. 
Efficacy of oncofertility consulting
Time from diagnosis to oncofertility consultation in 
our Clinic ranged from two days to four years in one 
case (patient with Hodgkin lymphoma, after chemo-
therapy, not included to the programme due to docu-
mented loss of fertility). After exclusion of that case in 
the statistics, mean time from diagnosis to oncofertility 
consultation was 55 days, and the median value was 
23 days. 
All of the patients were referred to the infertility 
treatment centres on the day of the consultation in the 
Clinic. The time from first oncofertility consultation to 
oocyte retrieval varied from 25 to 63 days, mean time 
was 45 days. The patient qualified for ovarian tissue 
cryopreservation had the sample retrieved seven days 
after the consultation. The time from fertility preserva-
tion procedure to onset of the treatment varied from 
three to six days, mean time five days.
All the patients underlined their positive attitude 
towards the consultations, regardless of whether they 
were included in the programme and finally underwent 
oncofertility procedures. As all of them claim that taking 
into consideration aspects of fertility while facing a seri-
ous diagnosis helped reduce stress and improve their gen-
eral attitude towards treatment and vision for overcom-
ing the disease. Two patients who could not be included 
in the programme for medical reasons expressed regret-
ted that they were not informed about fertility-sparing 
options while it was still possible to perform them. 
The most frequently reported drawback of the pro-
gramme concerned the financial aspect of the fertility 
preservation because all the costs associated with fer-
tility preservation procedures had to be covered by the 
patient.
Discussion
Based on current medical standards, the following 
methods of fertility preservation are available for wom-
en: embryo cryopreservation, oocyte cryopreservation, 
ovarian tissue cryopreservation, ovarian transposition, 
hormonal suppression, and fertility sparing surgery.
Methods of choice are embryo cryopreservation and 
oocyte cryopreservation. Both require undergoing hor-
monal stimulation in order to retrieve mature oocytes 
and optionally perform in vitro fertilisation. In particu-
lar medical conditions hormonal stimulation may be 
contraindicated (i.e. hormonal sensitive cancers) or an 
immediate onset of therapy may be necessary, not leav-
ing time for hormonal stimulation [5, 6]. Nevertheless, 
there are reports of beneficial effect of letrozole and ta-
moxifen during hormonal stimulation in breast cancer 
patients [7-11].
Consulted patients who did not undergo oncofertility procedures
Patients who underwent oncofertility procedures
Fig. 3. Number of patients who finally underwent oncofertility 
procedures
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Ovarian tissue cryopreservation is still an experi-
mental method. This procedure can be offered only as 
part of a clinical trial. It can be implicated in girls in pre-
pubertal age and does not require a delay in the onset 
of therapy [12].
Operative ovarian transposition outside the smaller 
pelvis may be considered in patients before planned ra-
diation on this region, and it should be performed as 
close to the beginning of the treatment as possible, due 
to the risk of dislocation of the ovaries [13].
In selected patients requiring surgical treatment the 
extent of surgery may be adjusted to the patient’s pro-
creative plans.
Hormonal suppression is not routinely recommended 
because its effectiveness remains controversial [14, 15].
The problem of fertility issues being inadequately 
addressed results in low referral rates to oncofertil-
ity programmes. This problem is reported by authors 
worldwide [16, 17]. However, in a  single oncofertility 
centre in Milan a  total of 96 patients were consulted 
during a period of three years [16]. A report from Gifu 
Prefecture in Japan details 81 patients consulted in 
an oncofertility clinic in Gifu University Hospital dur-
ing a  two-year period, referred from the 35 hospitals 
providing cancer treatment in that region [17]. As the 
report shows, the number of referred patients is con-
stantly growing, indicating an increasing awareness of 
the aspect of future fertility among oncologists.
The reason why such a small number of patients is 
being consulted in our Clinic may be due to the fact that 
some patients are referred straight to the fertility treat-
ment centres, omitting consultation in our Clinic. This, 
however, deprives the patient of the option to choose 
ovarian tissue cryopreservation as a fertility-preserving 
method. It can only be performed as part of a registered 
clinical trial, as it is in our Clinic. 
As reports show, there are several obstacles on the 
path to fertility preservation. The most frequently men-
tioned barrier is the financial aspect of the procedure. 
In Poland it is not covered by national health insurance 
and requires an approximate expense of several hundred 
zloty (over 5000 USD). In the overwhelming majority of 
countries, with the exception of Denmark, France, Ger-
many, the Netherlands, and Spain in Europe and Canada, 
Panama, and Argentina worldwide, oncofertility proce-
dures are not covered by national health insurance [18].
A noticeably impaired aspect shown in our study is 
the time from diagnosis to oncofertility consultation. 
According to all oncofertility standards and recommen-
dations, it should be organised as soon as possible after 
diagnosis. In our Clinic the time ranged from two days 
to four years in one case. After exclusion of that case in 
the statistics, mean time from diagnosis to oncofertility 
consultation was 55 days, and the median value was 
23 days.
Worldwide, most patients (35%) are referred to on-
cofertility specialist within 1-2 days of diagnosis. 78% 
see the specialist within one week [18].
In our Clinic the mean time from fertility preserva-
tion consultation to fertility preservation ranged from 
25 to 63 days. Worldwide, most patients have fertility 
preservation procedures performed within 1-5 days 
(46%), 83% within two weeks.
Cancer treatment is a  priority, and the therapy 
should not be delayed. Oncologists should have the de-
cisive vote on whether to postpone the onset of cancer 
treatment because of fertility-sparing procedures [17]. 
Therefore, it is essential to start cancer treatment as 
soon as possible after preserving fertility. In our Clin-
ic the time from fertility preservation to onset of the 
treatment varied from three to six days, with mean 
time of five days. Most patients worldwide start their 
treatment within 3-5 days after fertility preservation 
(27%), 67% of them within one week [18].
The fact that draws attention is that although many 
patients are consulted for the possibility of preserving 
fertility, finally only a minority of them undergo these 
procedures. In our Clinic this comprised just four pa-
tients out of 18 consulted (22%). Similar results were 
observed in Gifu Prefecture in Japan, where 70% of the 
patients consulted in an oncofertility centre finally did 
not decide to undergo fertility-sparing procedures [17]. 
This implies that making decisions about fertility pres-
ervation is a complex process and numerous external 
factors, e.g. clinical context, may have an influence.
Future studies or recommendations 
Subsequent studies should include multicentre 
analysis and longer observation time because this will 
provide more objective data. 
Constant discussion with oncologists and other 
specialists is necessary to spread awareness of the sig-
nificance for the patient of the aspect of fertility preser-
vation. It should be stressed that the oncological treat-
ment is always a priority.
Strengths and limitations of the study 
The study presents observations of newly intro-
duced type of health care service. This early analysis 
may act as a reference for other centres providing medi-
cal assistance in the field of oncofertility. 
The presented study is not free from points that 
need to be further developed. More patients should be 
involved in the analysis to provide more adequate eval-
uation of performance of the programme. Furthermore, 
the time horizon of the analysis limits the spectrum of 
obstetrical observations.
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Conclusions
Cancer treatment is increasingly effective, enabling 
patients to live longer. Therefore, loss of fertility be-
comes a serious adverse effect of the therapy for young 
patients. Fortunately, reproductive medicine offers vari-
ous methods of preserving fertility for the time that the 
treatment is completed. What is essential for the suc-
cess of fertility sparing is timely referral from oncolo-
gist to an oncofertility centre, before cancer treatment 
is started.
Attempts to raise awareness of oncofertility possi-
bilities among oncologists and other specialists should 
be undertaken because critically few patients are be-
ing referred to oncofertility centres. Once the patient 
is qualified for fertility preservation, further procedures 
are performed efficiently.
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